Ulipristal Acetate for Cervical Preparation

Phase 0 Completed 13 enrolled Stanford University

NaSingle-groupOpen-labelOther

Summary

This is a prospective cohort study exploring a broadened use of ulipristal acetate as a cervical preparation agent for second trimester surgical abortion. Specifically, this pilot study will test the feasibility of using ulipristal as a pharmacologic cervical preparation with adjunct misoprostol prior to surgical abortion.

Timeline

Start: 2019-04-16
Primary completion: 2020-04-02
Completion: 2020-04-02

Publications

Peterson SF, Lerma K, Shaw KA, Blumenthal PD. Cervical Preparation Using Ulipristal Acetate With Adjunct Misoprostol in Second-Trimester Surgical Abortions. Obstet Gynecol. 2022 May 1;139(5):907-909. doi: 10.1097/AOG.0000000000004754. Epub 2022 Apr 5. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ulipristal Acetate	Unknown	90 mg	Oral

Indications

No indication recorded.